Predicting the response of multiple myeloma to the proteasome inhibitor Bortezomib by evaluation of the unfolded protein response

Predicting the response of multiple myeloma to the proteasome inhibitor Bortezomib by evaluation of the unfolded protein response

[1]  B. Pégourié,et al.  Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  N. Nikesitch,et al.  Molecular mechanisms in multiple myeloma drug resistance , 2015, Journal of Clinical Pathology.

[3]  S. Harrison,et al.  Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1 , 2012, Haematologica.

[4]  J. Klco,et al.  Transcription factor MIST1 in terminal differentiation of mouse and human plasma cells. , 2011, Physiological genomics.

[5]  M. Dimopoulos,et al.  Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. , 2011, Blood.

[6]  U. Ozcan,et al.  Unfolded Protein Response Signaling and Metabolic Diseases* , 2013, The Journal of Biological Chemistry.

[7]  E. Zamagni,et al.  Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes , 2013, Annals of Hematology.

[8]  A. Belch,et al.  High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program , 2009, British journal of haematology.

[9]  D. Esseltine,et al.  A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. , 2014, Blood.